

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/511,484
				Filing Date	October 15, 2004
				First Named Inventor	Jabbour et al.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	11	Attorney Docket Number	20747/200 (ARDBW/P28269US)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
OK	1	US-3,840,597	10-08-1974	Moore et al.	
	2	US-4,233,299	11-11-1980	Trummlitz et al.	
	3	US-4,342,756	08-03-1982	Collington et al.	
	4	US-5,912,006	06-15-1999	Bockow et al.	
	5	US-5,955,575	09-21-1999	Peri et al.	
	6	US-6,197,327 B1	03-06-2001	Harrison et al.	
	7	US-6,211,221 B1	04-03-2001	Peterson et al.	
	8	US-6,441,033 B1	08-27-2002	Sharif et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
OK	9	EP 0 128 479 A2	12-19-1984	Rettegi et al.		
OK	10	EP 1 097 922 A1	05-09-2001	Maruyama et al.		
OK	11	EP 1 114 816 A1	07-11-2001	Maruyama et al.		
OK	12	GB 2 028 805 A	03-12-1980	Collington et al.		
OK	13	GB 2 092 144 A	08-11-1982	Schroder et al.		
OK	14	GB 2 330 307 A	04-21-1999	Foord et al.		
X	15	JP 01199958	08-11-1989	Yoshimitsu et al.		X
X	16	JP 1050818	02-27-1989	Kiyoshi et al.		X
X	17	JP 04077480	03-11-1992	Yoshimitsu et al.		X
X	18	JP 03083081	04-13-1988	Yoshimitsu et al.		X
X	19	JP 8176134	07-09-1996	Yoshimitsu et al.		X
OK	20	WO 91/13875	09-19-1991	Kajihara et al.		X
OK	21	WO 97/31631	09-04-1997	Bennett et al.		
	22	WO 98/16227	04-23-1998	Seibert et al.		
	23	WO 99/32640	07-01-1999	Chemtob et al.		
	24	WO 00/17348	03-30-2000	Chemtob et al.		
	25	WO 00/18405	04-06-2000	Baxter et al.		
	26	WO 00/18744	04-06-2000	Hattori et al.		
	27	WO 00/21532	04-20-2000	Harada et al.		
	28	WO 01/10426 A2	02-15-2001	Clayton et al.		
	29	WO 01/42281 A1	06-14-2001	Peri et al.		
	30	WO 01/72302 A1	10-04-2001	Baxter et al.		
	31	WO 01/90086 A1	11-29-2001	Hara et al.		
OK	32	WO 02/20020 A1	03-14-2002	Di Salle et al.		
OK	33	WO 03/030911 A1	04-17-2003	Jabbour		
OK	34	WO 03/037348 A1	05-08-2003	Jabbour et al.		
Examiner Signature	Daniel Rubenstein			Date Considered	12-17-07	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/511,484
				Filing Date	October 15, 2004
				First Named Inventor	Jabbour et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	2	of	11	Attorney Docket Number	20747/200 (ARDBW/P28269US)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	35	ABEL & BAIRD, "The Effect of 17 $\beta$ -Estradiol and Progesterone on Prostaglandin Production by Human Endometrium Maintained in Organ Culture," <i>Endocrinology</i> 106(5):1599-1606 (1980)	
	36	ADELANTADO et al., "Increased Uterine Prostaglandin E Receptors in Menorrhagic Women," <i>Br. J. Obstet. Gynaecol.</i> 95:162-165 (1988)	
	37	ARNOULD et al., "PGF <sub>2<math>\alpha</math></sub> , a Prostanoid Released by Endothelial Cells Activated by Hypoxia, Is a Chemoattractant Candidate for Neutrophil Recruitment," <i>Am. J. Pathol.</i> 159(1):345-357 (2001)	
	38	ASHBY, B., "Co-expression of Prostaglandin Receptors with Opposite Effects," <i>Biochem. Pharmacol.</i> 55:239-246 (1998)	
	39	BAUER et al., "High Cyclooxygenase 1 (COX-1) and Cyclooxygenase 2 (COX-2) Contents in Mouse Lung Tumors," <i>Carcinogenesis</i> 21(4):543-550 (2000)	
	40	BAUKNECHT, T., "Die Klinische Bedeutung Membranständiger Rezeptoren beim Ovarialkarzinom," <i>Onkologie</i> 7(Suppl. 2):54-57 (1984) (English abstract)	X
	41	BERG et al., "Signal Transduction Difference Between 5-Hydroxytryptamine Type 2A and Type 2C Receptor Systems," <i>Mol. Pharmacol.</i> 46:477-484 (1994)	
	42	BITO, L.Z., "Prostaglandins: A New Approach to Glaucoma Management with a New, Intriguing Side Effect," <i>Surv. Ophthalmol.</i> 41(Suppl. 2):S1-S14 (1997)	
	43	CHEN et al., "Identification of a Prostanoid FP Receptor Population Producing Endothelium-dependent Vasorelaxation in the Rabbit Jugular Vein," <i>Br. J. Pharmacol.</i> 116:3035-3041 (1995)	
	44	CHEN et al., "Prostaglandin F <sub>2<math>\alpha</math></sub> Stimulates the Raf/MEK1/Mitogen-Activated Protein Kinase Signaling Cascade in Bovine Luteal Cells," <i>Endocrinology</i> 139(9):3876-3885 (1998)	
	45	CHENG et al., "Prostaglandine E <sub>2</sub> Induces Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor mRNA Expression in Cultured Rat Müller Cells," <i>Invest. Ophthalmol. Vis. Sci.</i> 39(3):581-591 (1998)	
	46	COLEMAN et al., "International Union of Pharmacology Classification of Prostanoid Receptors: Properties, Distribution, and Structure of the Receptors and Their Subtypes," <i>Pharmacol. Rev.</i> 46(2):205-229 (2001)	

Examiner Signature		Date Considered	12-17-07
--------------------	--	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/511,484
				Filing Date	October 15, 2004
				First Named Inventor	Jabbour et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	3	of	11	Attorney Docket Number	20747/200 (ARDBW/P28269US)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	47	DAI et al., "Molecular Tools to Reestablish Progesterone Control of Endometrial Cancer Cell Proliferation," <i>Am. J. Obstet. Gynecol.</i> 184(5):790-797 (2001)	
	48	DAVIS & SHARIF, "Quantitative Autoradiographic Visualization and Pharmacology of FP-Prostaglandin Receptors in Human Eyes Using the Novel Phosphor-Imaging Technology," <i>J. Ocular Pharmacol. Ther.</i> 15(4):323-336 (1999)	
	49	DEAN et al., "p38 Mitogen-activated Protein Kinase Regulates Cyclooxygenase-2 mRNA Stability and Transcription in Lipopolysaccharide-treated Human Monocytes," <i>J. Biol. Chem.</i> 274(1):264-269 (1999)	
	50	DELAEY & VAN DE VOORDE, "Prostanoid-Induced Contractions are Blocked by Sulfonylureas," <i>Eur. J. Pharmacol.</i> 280:179-184 (1995)	
	51	DEROSSI et al., "Trojan Peptides: The Penetratin System for Intracellular Delivery," <i>Trends Cell Biol.</i> 8:84-87 (1998)	
	52	DeWITT, D.L., "Prostaglandin Endoperoxide Synthase: Regulation of Enzyme Expression," <i>Biochim. Biophys. Acta</i> 1083:121-134 (1991)	
	53	DONG & YALLAMPALLI, "Pregnancy and Exogenous Steroid Treatments Modulate the Expression of Relaxant EP <sub>2</sub> and Contractile FP Receptors in the Rat Uterus," <i>Biol. Reprod.</i> 62:533-539 (2000)	
	54	DORÉ et al., "Expression of Prostaglandin G/H Synthase Type 1, but not Type 2, in Human Ovarian Adenocarcinomas," <i>J. Histochem. Cytochem.</i> 46(1):77-84 (1998)	
	55	DUNN & GOA, "Tranexamic Acid. A Review of Its Use in Surgery and Other Indications," <i>Drugs</i> 57(6):1005-1032 (1999)	
	56	FORSBERG et al., "Human Glutathione Dependent Prostaglandin E Synthase: Gene Structure and Regulation," <i>FEBS Lett.</i> 471:78-82 (2000)	
	57	FORTIER & GRASSO, "Specific Properties of Epithelial and Stromal Cells from the Endometrium of Cows," <i>J. Reprod. Fert.</i> 83:239-248 (1988)	
	58	FRASER et al., "Long-Term Treatment of Menorrhagia with Mefenamic Acid," <i>Obstetrics &amp; Gynecology</i> 61(1):109-112 (1983)	
	59	GORDON & IRELAND, "Pathology of Hyperplasia and Carcinoma of the Endometrium," <i>Semin. Oncol.</i> 21(1):64-70 (1994)	

Examiner Signature		Date Considered	12-17-07
--------------------	--	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/511,484
				Filing Date	October 15, 2004
				First Named Inventor	Jabbour et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	4	of	11	Attorney Docket Number	20747/200 (ARDBW/P28269US)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	60	GRIFFIN et al., "AL-8810: A Novel Prostaglandin F <sub>2α</sub> Analog with Selective Antagonist Effects at the Prostaglandin F <sub>2α</sub> (FP) Receptor," <i>J. Pharmacol. Exp. Ther.</i> 290(3):1278-1284 (1999)	
	61	GRIFFIN et al., "FP Prostaglandin Receptors Mediating Inositol Phosphates Generation and Calcium Mobilization in Swiss 3T3 Cells: A Pharmacological Study," <i>J. Pharmacol. Exp. Ther.</i> 281(2):845-854 (1997)	
	62	GRIFFIN et al., "Pharmacological Characterization of an FP Prostaglandin Receptor on Rat Vascular Smooth Muscle Cells (A7r5) Coupled to Phosphoinositide Turnover and Intracellular Calcium Mobilization," <i>J. Pharmacol. Exp. Ther.</i> 286(1):411-418 (1998)	
	63	GUPTA et al., "Over-expression of Cyclooxygenase-2 in Human Prostate Adenocarcinoma," <i>The Prostate</i> 42:73-78 (2000)	
	64	HELLBERG et al., "Preclinical Efficacy of AL-6221, a Potent and Selective FP Prostaglandin Agonist," <i>Invest. Ophthalmol. Vis. Sci.</i> 39(4):S420 (1998) (Abstract #1961)	
	65	HERSCHMAN, H.R., "Prostaglandin Synthase 2," <i>Biochim. Biophys. Acta</i> 1299:125-140 (1996)	
	66	HILLOCK & CRANKSHAW, "Inhibitory Prostanoid EP Receptors in Human Non-pregnant Myometrium," <i>Eur. J. Pharmacol.</i> 378:99-108 (1999)	
	67	HOFMAN et al., "Topography of Human Uterine Prostaglandin E and F <sub>2α</sub> Receptors and Their Profiles during Pathological States," <i>J. Clin. Endocrinol. Metabol.</i> 57(2):360-366 (1983)	
	68	HÖPER et al., "Prostaglandins Induce Vascular Endothelial Growth Factor in a Human Monocytic Cell Line and Rat Lungs via cAMP," <i>Am. J. Respir. Cell Mol. Biol.</i> 17:748-756 (1997)	
	69	HOYER et al., "Ovine Prostaglandin F <sub>2α</sub> Receptor," <i>Endocrine</i> 10(2):105-111 (1999)	
	70	JABBOUR et al., "Expression and Localisation of Cox-2 and Prostaglandin E in Endometrial Adenocarcinoma," <i>J. Pathology</i> 189:5A (1999)	
	71	JABBOUR et al., "Expression of COX-2 and PGE Synthase and Synthesis of PGE <sub>2</sub> in Endometrial Adenocarcinoma: A Possible Autocrine/Paracrine Regulation of Neoplastic Cell Function via EP2/EP4 Receptors," <i>British Journal of Cancer</i> 85(7):1023-1031 (2001)	

Examiner Signature		Date Considered	12-17-07
--------------------	--	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/511,484
				Filing Date	October 15, 2004
				First Named Inventor	Jabbour et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	5	of	11	Attorney Docket Number	20747/200 (ARDBW/P28269US)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	72	JAKOBSSON et al., "Identification of Human Prostaglandin E Synthase: A Microsomal, Glutathione-dependent, Inducible Enzyme, Constituting a Potential Novel Drug Target," <i>Proc. Natl. Acad. Sci. USA</i> 96:7220-7225 (1999)	
	73	JANSSENS et al., "Effect of Ridogrel on Vascular Contractions Caused by Vasoactive Substances Released during Platelet Activation," <i>Thrombosis and Haemostasis</i> 64(1):91-96 (1990)	
	74	JONES et al., "Chemokine and Cyclooxygenase-2 Expression in Human Endometrium Coincides with Leukocyte Accumulation," <i>Hum. Reprod.</i> 12(6):1300-1306 (1997)	
	75	JONES et al., "HGF Triggers Activation of the COX-2 Gene in Rat Gastric Epithelial Cells: Action Mediated Through the ERK2 Signaling Pathway," <i>FASEB J.</i> 13:2186-2194 (1999)	
	76	JONES et al., "Inhibition of Angiogenesis by Nonsteroidal Anti-Inflammatory Drugs: Insight into Mechanisms and Implications for Cancer Growth and Ulcer Healing," <i>Nat. Med.</i> 5(12):1418-1423 (1999)	
	77	KANAOKA et al., "Cloning and Crystal Structure of Hematopoietic Prostaglandin D Synthase," <i>Cell</i> 90:1085-1095 (1997)	
	78	KENAKIN, T., "The Classification of Seven Transmembrane Receptors in Recombinant Expression Systems," <i>Pharmacol. Rev.</i> 48(3):413-463 (1996)	
	79	KITAMURA et al., "Inhibitory Effects of Mofezolac, a Cyclooxygenase-1 Selective Inhibitor, on Intestinal Carcinogenesis," <i>Carcinogenesis</i> 23(9):1463-1466 (2002)	
	80	KITANAKA et al., "Phloretin as an Antagonist of Prostaglandin F <sub>2a</sub> Receptor in Cultured Rat Astrocytes," <i>J. Neurochem.</i> 60(2):704-708 (1993)	
	81	KULKARNI et al., "Cyclooxygenase-2 is Overexpressed in Human Cervical Cancer," <i>Clin. Cancer Res.</i> 7:429-434 (2001)	
	82	KUMAR et al., "Selective Down-Regulation of Progesterone Receptor Isoform B in Poorly Differentiated Human Endometrial Cancer Cells: Implication for Unopposed Estrogen Action," <i>Cancer Res.</i> 58:1860-1865 (1998)	
	83	LEVITT et al., "Prostaglandin Content of Human Endometrium," <i>Fertil. Steril.</i> 26(3):296-300 (1975)	

Examiner Signature		Date Considered	12-17-07
--------------------	--	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/511,484
				Filing Date	October 15, 2004
				First Named Inventor	Jabbour et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	6	of	11	Attorney Docket Number	20747/200 (ARDBW/P28269US)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	84	LI et al., "Knockout of the Murine Prostaglandin EP <sub>2</sub> Receptor Impairs Osteoclastogenesis in Vitro," <i>Endocrinology</i> 141(6):2054-2061 (2000)	
	85	LIM et al., "Differential Localization and Activity of the A- and B-forms of the Human Progesterone Receptor Using Green Fluorescent Protein Chimeras," <i>Mol. Endocrinol.</i> 13(3):366-375 (1999)	
	86	MAATHUIS, J.B., "Cyclic Changes in the Concentration of Prostaglandin F <sub>2α</sub> In Human Uterine Flushings," <i>Br. J. Obstet. Gynaecol.</i> 85:207-210 (1978)	
	87	MACHWATE et al., "Prostaglandin Receptor EP <sub>4</sub> Mediates the Bone Anabolic Effects of PGE <sub>2</sub> ," <i>Mol. Pharmacol.</i> 60(1):36-41 (2001)	
	88	MANT & VESSEY, "Ovarian and Endometrial Cancers," <i>Cancer Surv.</i> 20:287-307 (1994)	
	89	MARIONS & DANIELSSON, "Expression of Cyclo-oxygenase in Human Endometrium During the Implantation Period," <i>Mol. Hum. Reprod.</i> 5(10):961-965 (1999)	
	90	MASFERRER et al., "Antiangiogenic and Antitumor Activities of Cyclooxygenase-2 Inhibitors," <i>Cancer Res.</i> 60:1306-1311 (2000)	
	91	MILNE et al., "Expression, Localization, Signaling of PGE <sub>2</sub> and EP <sub>2</sub> /EP <sub>4</sub> Receptors in Human Nonpregnant Endometrium Across the Menstrual Cycle," <i>J. Clin. Endocrinol. Metab.</i> 86(9):4453-4459 (2001)	
	92	MILNE, S.A., "Prostaglandin F <sub>2α</sub> (PGF) Receptor (FP) Expression in Normal and Adenocarcinoma Uterine Tissue: Role of PGF in Epithelial Cell Proliferation Via Phospholipase C (PLC)," <i>The Endocrine Society's 84<sup>th</sup> Annual Meeting</i> , Abstract #851905 (2002)	
	93	MIYATA et al., "Molecular Cloning and Expression of Human Prostacyclin Synthase," <i>Biochem. Biophys. Res. Commun.</i> 200(3):1728-1734 (1994)	
	94	MOHAMMED et al., "Expression of Cyclooxygenase-2 (COX-2) in Human Invasive Transitional Cell Carcinoma (TCC) of the Urinary Bladder," <i>Cancer Res.</i> 59:5647-5650 (1999)	
	95	MUNIR et al., "Expression of Cyclooxygenase 2 by Prostaglandin E <sub>2</sub> in Human Endometrial Adenocarcinoma Cell Line HEC-1B," <i>Biol. Reprod.</i> 63:933-941 (2000)	
Examiner Signature			Date Considered
			12-17-07

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/511,484
				Filing Date	October 15, 2004
				First Named Inventor	Jabbour et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	7	of	11	Attorney Docket Number	20747/200 (ARDBW/P28269US)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	96	NARUMIYA & FITZGERALD, "Genetic and Pharmacological Analysis of Prostanoid Receptor Function," <i>J. Clin. Invest.</i> 108(1):25-30 (2001)	
	97	NOYES et al., "Dating the Endometrial Biopsy," <i>Fertil. Steril.</i> 1:3-25 (1950)	
	98	O'BANION et al., "A Serum- and Glucocorticoid-regulated 4-Kilobase mRNA Encodes a Cyclooxygenase-related Protein," <i>J. Biol. Chem.</i> 266(34):23261-23267 (1991)	
	99	OCKLIND et al., "Localization of the Prostaglandin F <sub>2α</sub> Receptor Messenger RNA and Protein in the Cynomolgus Monkey Eye," <i>Invest. Ophthalmol. Vis. Sci.</i> 37(5):716-726 (1996)	
	100	ORLICKY et al., "A Role for Prostaglandins in Estrogen Growth Regulation," <i>Medical Hypotheses</i> 25:1-5 (1988)	
	101	OTA et al., "Distribution of Cyclooxygenase-2 in Eutopic and Ectopic Endometrium in Endometriosis and Adenomyosis," <i>Human Reprod.</i> 16(3):561-566 (2001)	
	102	OU et al., "Expression and Regulation of the Messenger Ribonucleic Acid Encoding and Prostaglandin F <sub>2α</sub> Receptor in the Rat Myometrium During Pregnancy and Labor," <i>Am. J. Obstet. Gynecol.</i> 182:919-925 (2000)	
	103	OYAMADA, T., "Levels of Prostaglandin F <sub>2α</sub> , E <sub>2</sub> in the Human Uterine Tissues and in Human Fallopian Tubes from Nonpregnant Women," <i>Acta Obst. Gynaec. Jpn.</i> 33(1):155-160 (1981)	
	104	PELLETIER et al., "Prostaglandin E <sub>2</sub> Increases Cyclic AMP and Inhibits Endothelin-1 Production/Secretion by Guinea-Pig Tracheal Epithelial Cells through EP <sub>4</sub> Receptors," <i>Br. J. Pharmacol.</i> 132:999-1008 (2001)	
	105	PERSSON, I., "Estrogens in the Causation of Breast, Endometrial and Ovarian Cancers — Evidence and Hypotheses from Epidemiological Findings," <i>J. Steroid Biochem. Mol. Biol.</i> 74:357-364 (2000)	
	106	QUINIOU et al., "PH113 is a Selective PGF <sub>2α</sub> Receptor Antagonist Which Delays Preterm Labor," <i>Pediatric Research</i> 49(2):452A (2001) (Abstract #2593)	
	107	RATNASINGHE et al., "Expression of Cyclooxygenase-2 in Human Adenocarcinomas of the Gastric Cardia and Corpus," <i>Oncol. Rep.</i> 6:965-968 (1999)	

Examiner Signature		Date Considered	12-17-07
--------------------	--	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/511,484
				Filing Date	October 15, 2004
				First Named Inventor	Jabbour et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	8	of	11	Attorney Docket Number	20747/200 (ARDBW/P28269US)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DL	108	REES et al., "Effect of Fenamates on Prostaglandin E Receptor Binding," <i>The Lancet</i> 2(8610):541-542 (1988)	
DL	109	REES et al., "Endometrial and Myometrial Prostaglandin Release during the Menstrual Cycle in Relation to Menstrual Blood Loss," <i>J. Clin. Endocrinol. Metab.</i> 58(5):813-818 (1984)	
DL	110	REES et al., "Immunohistochemical Localization of Cyclooxygenase in the Human Uterus," <i>Prostaglandins</i> 23:207-214 (1982)	
DL	111	RIOUX & CASTONGUAY et al., "The Induction of Cyclooxygenase-1 by a Tobacco Carcinogen in U937 Human Macrophages is Correlated to the Activation of NF-κB," <i>Carcinogenesis</i> 21(9):1745-1751 (2000)	
DL	112	ROLLAND et al., "Prostaglandin in Human Breast Cancer: Evidence Suggesting That and Elevated Prostaglandin Production Is a Marker of High Metastatic Potential for Neoplastic Cells," <i>J. Natl. Cancer. Inst.</i> 64(5):1061-1070 (1980)	
DL	113	RYU et al., "High Cyclooxygenase-2 Expression in Stage IB Cervical Cancer with Lymph Node Metastasis or Parametrial Invasion," <i>Gynecologic Oncology</i> 76:320-325 (2000)	
DL	114	SALES et al., "Cyclooxygenase-2 Expression and Prostaglandin E <sub>2</sub> Synthesis Are Up-Regulated in Carcinomas of the Cervix: A Possible Autocrine/Paracrine Regulation of Neoplastic Cell Function via EP2/EP4 Receptors," <i>J. Clin. Endocrinol. Metab.</i> 86(5):2243-2249 (2001)	
DL	115	SASAKI et al., "Progesterone Receptor B Gene Inactivation and CpG Hypermethylation in Human Uterine Endometrial Cancer," <i>Cancer Res.</i> 61:97-102 (2001)	
DL	116	SENIOR et al., "In vitro Characterization of Prostanoid Receptors on Human Myometrium at Term Pregnancy," <i>Br. J. Pharmacol.</i> 108:501-506 (1993)	
DL	117	SHARIF et al., "[ <sup>3</sup> H]AL-5848 ([ <sup>3</sup> H]9β-(+)-Fluprostenol). Carboxylic Acid of Travoprost (AL-6221), a Novel FP Prostaglandin to Study the Pharmacology and Autoradiographic Localization of the FP Receptor," <i>J. Pharm. Pharmacol.</i> 51:685-694 (1999)	
DL	118	SHARIF et al., "AL-3138 Antagonizes FP Prostanoid Receptor-mediated Inositol Phosphates Generation: Comparison with Some Purported FP Antagonists," <i>J. Pharm. Pharmacol.</i> 52:1529-1539 (2000)	

Examiner Signature	David Lukyan	Date Considered	12-17-07
-----------------------	--------------	--------------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/511,484
				Filing Date	October 15, 2004
				First Named Inventor	Jabbour et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	9	of	11	Attorney Docket Number	20747/200 (ARDBW/P28269US)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	119	SHARIF et al., "Bimatoprost and Its Free Acid Are Prostaglandin FP Receptor Agonists," <i>Eur. J. Pharmacol.</i> 432:211-213 (2001)	
	120	SHARIF et al., "Pharmacology of [ <sup>3</sup> H]Prostaglandin E <sub>1</sub> /[ <sup>3</sup> H]Prostaglandin E <sub>2</sub> and [ <sup>3</sup> H]Prostaglandin F <sub>2α</sub> Binding to EP <sub>3</sub> and FP Prostaglandin Receptor Binding Sites in Bovine Corpus Luteum: Characterization and Correlation with Functional Data," <i>J. Pharmacol. Exp. Ther.</i> 286(2):1094-1102 (1998)	
	121	SOLER et al., "Human Vascular Smooth Muscle Cells but Not Endothelial Cells Express Prostaglandin E Synthase," <i>Circ. Res.</i> 87:504-507 (2000)	
	122	STINGER et al., "Selective Antagonism of Prostaglandin F <sub>2α</sub> -Mediated Vascular Responses by N-Dimethylamino Substitution of Prostaglandin F <sub>2α</sub> ," <i>J. Pharmacol. Exp. Ther.</i> 220(3):521-525 (1982)	
	123	STIRRAT, G.M., "Choice of Treatment for Menorrhagia," <i>The Lancet</i> 353:2175-2176 (1999)	
	124	STOCCO et al., "A Calcium/Calmodulin-dependent Activation of ERK1/2 Mediates JunD Phosphorylation and Induction of <i>nur77</i> and <i>20-hsd</i> Genes by Prostaglandin F <sub>2</sub> in Ovarian Cells," <i>J. Biol. Chem.</i> 277(5):3293-3302 (2002)	
	125	SUBBARAMAIAH et al., "Transcription of Cyclooxygenase-2 Is Enhanced in Transformed Mammary Epithelial Cells," <i>Cancer Res.</i> 56:4424-4429 (1996)	
	126	SUGIMOTO et al., "Failure of Parturition in Mice Lacking the Prostaglandin F Receptor," <i>Science</i> 277:681-683 (1997)	
	127	SUZUKI-YAMAMOTO et al., "cDNA Cloning, Expression and Characterization of Human Prostaglandin F Synthase," <i>FEBS Lett.</i> 462:335-340 (1999)	
	128	TANIOKA et al., "Molecular Identification of Cytosolic Prostaglandin E <sub>2</sub> Synthase That Is Functionally Coupled with Cyclooxygenase-1 in Immediate Prostaglandin E <sub>2</sub> Biosynthesis," <i>J. Biol. Chem.</i> 275(42):32775-32782 (2000)	
	129	THORÈN & JAKOBSSON et al., "Coordinate Up- and Down-Regulation of Glutathione-Dependent Prostaglandin E Synthase and Cyclooxygenase-2 in A549 Cells. Inhibition by NS-398 and Leukotriene C <sub>4</sub> ," <i>Eur. J. Biochem.</i> 267:6428-6434 (2000)	

Examiner Signature		Date Considered	12-17-07
--------------------	--	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application Number	10/511,484
				Filing Date	October 15, 2004
				First Named Inventor	Jabbour et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	10	of	11	Attorney Docket Number	20747/200 (ARDBW/P28269US)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DL	130	TONG et al., "Heightened Expression of Cyclooxygenase-2 and Peroxisome Proliferation-Activated Receptor-δ in Human Endometrial Adenocarcinoma," <i>Neoplasia</i> 2(6):483-490 (2000)	
DL	131	TSANG et al., "Endometrial Prostaglandins and Menorrhagia: Influence of a Prostaglandin Synthetase Inhibitor in vivo," <i>Can. J. Physiol. Pharmacol.</i> 65:2081-2084 (1987)	
DL	132	TSUJI et al., "Evidences for Involvement of Cyclooxygenase-2 in Proliferation of Two Gastrointestinal Cancer Cell Lines," <i>Prostaglandins Leukot. Essent. Fatty Acids</i> 55(3):179-183 (1996)	
DL	133	TSUJI & DuBOIS, "Alterations in Cellular Adhesion and Apoptosis in Epithelial Cells Overexpressing Prostaglandin Endoperoxide Synthase 2," <i>Cell</i> 83:493-501 (1995)	
DL	134	TSUJI et al., "Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells," <i>Cell</i> 93:705-716 (1998)	
DL	135	TSUJI et al., "Cyclooxygenase-2 Expression in Human Colon Cancer Cells Increases Metastatic Potential," <i>Proc. Natl. Acad. Sci. USA</i> 94:3336-3340 (1997)	
DL	136	TUCKER et al., "Cyclooxygenase-2 Expression Is Up-Regulated in Human Pancreatic Cancer," <i>Cancer Res.</i> 59:987-990 (1999)	
DL	137	VAN VOORHIS et al., "Immunohistochemical Localization of Prostaglandin H Synthase in the Female Reproductive Tract and Endometriosis," <i>Am. J. Obstet. Gynecol.</i> 163:57-62 (1990)	
DL	138	VANE et al., "Cyclooxygenases 1 and 2," <i>Annu. Rev. Pharmacol. Toxicol.</i> 38:97-120 (1998)	
DL	139	VIJAYAKUMAR & WALTERS, "Myometrial Prostaglandins During the Human Menstrual Cycle," <i>Am. J. Obstet. Gynecol.</i> 141(3):313-318 (1981)	
DL	140	WEAVER et al., "Regulatory Role of Phosphatidylinositol 3-Kinase on TNF-α-Induced Cyclooxygenase 2 Expression in Colonic Epithelial Cells," <i>Gastroenterology</i> 120:1117-1127 (2001)	
DL	141	WILLMAN et al., "Studies in the Involvement of Prostaglandins in Uterine Symptomatology and Pathology," <i>Br. J. Obstet. Gynaecol.</i> 83(3):337-341 (1976)	

Examiner Signature	David R. Kohn	Date Considered	12-17-07
--------------------	---------------	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

Examiner Signature	<i>[Signature]</i>	Date Considered	12-17-07
-----------------------	--------------------	--------------------	----------

\* **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.